Research Grade Obinutuzumab ( 阿托珠单抗 )
- 发布日期： 2020-10-28
- 更新日期： 2025-10-24
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00150
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
949142-50-1
|
| 保质期 |
一年
|
| 抗体名 |
Obinutuzumab ( 阿托珠单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
MS4A1/CD20[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
1mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
货号（Catalog No.）
CSD00150
通用名INN
Obinutuzumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
别名(Alternative names)
GA101,RG7159,RO5072759,afutuzumab
靶点;物种(Specificity target name;species)
MS4A1/CD20[Homo sapiens]
活性研究（体外/体内研究）(Activity in vitro)
Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab.
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
分子量(MV)
150000.00 Da
CAS
949142-50-1
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
